Navigation Links
A possible pathway for inhibiting liver and colon cancer is found
Date:7/8/2014

A group of scientists from Spain, the UK and the United States has revealed the structure of a protein complex involved in liver and colon cancers. Both of these types of cancer are of significant social and clinical relevance as in 2012 alone, liver cancer was responsible for the second highest mortality rate worldwide, with colon cancer appearing third in the list.

The international team from CIC bioGUNE, the University of Liverpool and the US research centre USC-UCLA has successfully unravelled the mechanism by which two proteins, MATα2 and MATβ, bind to each other, thereby promoting the reproduction of tumour cells in liver and colon cancers. The study was published in the latest issue of the open access journal IUCrJ published by the IUCr [Murray et al. (2014). IUCrJ 1, 240-249; doi: 10.1107/S2052252514012585]

This structural data discovery opens up additional research opportunities into drugs that can act on the binding of these proteins, thereby possibly inhibiting cancer cell growth.

As a result of this discovery, it is now known which part of their respective structures can be blocked to prevent these proteins from joining together. This is very important as when these proteins bind to each other, the production of a molecule known as SAMe, which plays a role in uncontrolled tumour cell growth, increases considerably. Though the relationship between SAMe and tumour growth has been known for some time, this molecule also has other important functions inside the cell that cannot be altered and there is currently no way of acting against it without affecting these other life-sustaining functions.

The good news is that MATα2 and MATβ are only overexpressed in adults with tumours therefore representing an excellent therapeutic target which could open the door to the creation of highly targeted drugs that act exclusively by blocking those regions that allow their mutual binding rather than attacking other regions of the body.

The CIC bioGUNE researcher Adriana Rojas, who led this study, mentioned during interview "Many years have passed since it was first understood which proteins produce SAMe and how the levels of this molecule affect cancer cell growth, and we have now shown that the complex between MATα2 and MATβ is a possible therapeutic target".

The research involved X-ray crystallography and solution X-ray scattering techniques utilizing some of Europe's most powerful X-ray synchrotron sources, ALBA in Spain and SOLEIL and DIAMOND in the UK.


'/>"/>

Contact: Dr. Jonathan Agbenyega
ja@iucr.org
44-124-434-2878
International Union of Crystallography
Source:Eurekalert  

Related medicine news :

1. Possible new cancer treatment identified
2. Study identifies possible protective blood factors against Type 2 diabetes
3. First study investigating possible link between sunscreen ingredient and endometriosis
4. Scientists identify possible drug target for acute pancreatitis
5. High-contrast, high-resolution CT scans now possible at reduced dose
6. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
7. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
8. Higher energies for laser-accelerated particles possible
9. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
10. Mutation in gene IDH a possible target for AML treatment
11. Mild HIV type slows development of AIDS and makes new preventive treatments possible
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A possible pathway for inhibiting liver and colon cancer is found
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017   Divoti USA will ... to the standard of the latest FDA requirements, which stipulates new ... Anyone in need of Medical ID jewelry such as Medical ... are engraved in terms of the new FDA requirements ... Divoti offers this dark ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology: